Amgen (AMGN) vs Exelixis (EXEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Exelixis (EXEL) has outperformed Amgen (AMGN) over the past year, gaining 52.7% versus a gain of 39.8%. Over five years, EXEL leads with a +170.5% price change compared with +98.7% for AMGN. Amgen is the larger company by market cap ($220.28 billion vs $14.62 billion), about 15.1 times the size.
On valuation, Exelixis trades at a lower forward P/E (13.9x vs 16.6x for Amgen). Amgen pays a dividend yielding 2.41%, while Exelixis does not currently pay one. Exelixis converts more of its revenue into profit, with a net margin of 33.7% versus 21.0%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMGN | EXEL |
|---|---|---|
| Share price | $407.44 | $59.02 |
| Market cap | $220.28B | $14.62B |
| 1-day change | -1.37% | +0.99% |
| YTD return | +26.20% | +34.66% |
| 1-year return | +39.77% | +52.74% |
| 5-year return | +98.75% | +170.49% |
| P/E ratio (TTM) | 25.31 | 18.62 |
| Forward P/E | 16.65 | 13.92 |
| EPS (TTM) | $16.10 | $3.17 |
| Dividend yield | 2.41% | 0.00% |
| Annual dividend | $9.80 | $0.00 |
| Revenue (latest FY) | $36.75B | $2.32B |
| Revenue growth (YoY) | +9.95% | +6.98% |
| Net income (latest FY) | $7.71B | $782.57M |
| Gross margin | 67.25% | 96.39% |
| Operating margin | 24.71% | 37.59% |
| Net margin | 20.98% | 33.73% |
| 52-week high | $447.03 | $61.14 |
| 52-week low | $288.00 | $33.76 |
| Distance from 52-week high | -8.86% | -3.47% |
| Analyst consensus | hold | buy |
| Avg. price target upside | -3.92% | -7.61% |
| Average volume | 2.73M | 2.34M |
| Shares outstanding | 540.63M | 247.78M |
| Employees | 31,500 | 1,077 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- Amgen is about 15.1 times larger than Exelixis by market value ($220.28B vs $14.62B).
- EXEL has outperformed AMGN by 13.0 percentage points over the past year.
- Amgen trades at a higher earnings multiple (25.3x vs 18.6x trailing P/E).
- Amgen offers a meaningfully higher dividend yield (2.41% vs 0.00%).
- Exelixis is more profitable, keeping 33.7 cents of every revenue dollar as net income versus 21.0 cents for Amgen.
About Amgen
AMGN stock →Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 31,500 employees
About Exelixis
EXEL stock →Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,077 employees
AMGN vs EXEL FAQ
Which is bigger, Amgen or Exelixis?
Amgen (AMGN) is larger, with a market capitalization of $220.28B compared with $14.62B for Exelixis (EXEL).
Which stock has performed better over the past year, AMGN or EXEL?
EXEL returned +52.74% over the past 12 months, compared with +39.77% for AMGN (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, AMGN or EXEL?
EXEL has the lower trailing P/E at 18.6, versus 25.3 for AMGN. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Amgen or Exelixis?
Amgen pays a dividend yielding 2.41%, while Exelixis does not currently pay a regular dividend.
Are Amgen and Exelixis in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.